Citations

Mayo Clinic

Showing 10 of 108551 citations.

Predictive value of symptoms and signs in ulnar neuropathy at the elbow
Rubin, Devon I., Dimberg, Elliot L., Mauricio, Elizabeth A. , Gerpen, Jay A. van, Whitlock, Julia B., Mauricio, Elizabeth, Whitlock, Julia, Mauricio, Elizabeth A.

Muscle & Nerve | February 26, 2016 | Volume: 53 | Issue: 6 | Pages: 998-998

10.1002/mus.25086 | PMID 26917349 Get It

A longer duration of estrogen deficiency increases fibrosis risk among postmenopausal women with nonalcoholic fatty liver disease
Klair, Jagpal S. , Yang, Ju Dong , Abdelmalek, Manal F. , Guy, Cynthia D. , Yates, Katherine P. , Ünalp–Arida, Aynur , Lavine, Joel E. , Clark, Jeanne M. , Diehl, Anna Mae , Suzuki, Ayako , Yang, Ju Dong , Gill, Ryan M. , Abdelmalek, Manal , Suzuki, Ayako

Hepatology | February 26, 2016 | Volume: 64 | Issue: 1 | Pages: 85-91

10.1002/hep.28514 | PMID 26919573 Get It

Postmenopausal women with nonalcoholic steatohepatitis are at an increased risk of hepatic fibrosis compared with premenopausal women. Whether duration of estrogen deficiency in postmenopausal state dictates an individual's fibrosis risk remains uninvestigated. We assessed the associations of age at menopause and time from menopause with fibrosis severity in postmenopausal women with nonalcoholic fatty liver disease. Data from 488 postmenopausal women with (1) histologic diagnosis of nonalcoholic fatty liver disease and (2) self‐reported information on age at menopause were analyzed. The associations of premature menopause (age at menopause of <40 years) and time from menopause (age at study enrollment ‐ age at menopause, years) with fibrosis severity (stage 0‐4) were assessed using multiple ordinal logistic regression models with and without adjusting for clinical confounders. Among the participants (age at menopause 43.7 ± 8.6 years), women with premature menopause (29.3%) were younger at enrollment ( P < 0.001) and used hormone replacement therapy more often ( P < 0.003). After adjusting for age at enrollment, race, waist circumference standardized by body mass index, current smoking, current alcohol use, hypertension, diabetes/impaired fasting glucose, homeostatic model assessment of insulin resistance, and hormone replacement therapy, premature menopause was associated with an increased likelihood of having more severe fibrosis (adjusted cumulative odds ratio = 1.9, 95% confidence interval 1.3‐2.7, P = 0.001), while time from menopause was directly associated with an increased likelihood of having more severe fibrosis (adjusted cumulative odds ratio for 5‐year unit = 1.2, 95% confidence interval 1.1‐1.3, P = 0.002). Conclusion : Duration of estrogen deficiency in postmenopausal state confers fibrosis risk among postmenopausal women with nonalcoholic fatty liver disease. (H epatology 2016;64:85–91)
Foxa1 is essential for mammary duct formation
Zhao, Yongbing , Skerry, Benjamin, Wang, Xiao , Colin, Christelle , Li, Zhaoyu , Colin-Cassin, Christelle, Radisky, Derek C. , Liu, Yi , Kaestner, Klaus H. , Li, Zhaoyu

genesis | February 26, 2016 | Volume: 54 | Issue: 5 | Pages: 277-285

10.1002/dvg.22929 | PMID 26919034 Get It

Summary The transcription factor forkhead box protein A1 (FOXA1) plays a critical role in the proliferation of human breast cancer cells, particularly estrogen receptor alpha (ERα)‐positive luminal breast cancer cells. However, genetic studies of the requirement for Foxa1 in mammary tumor formation in mice have been hampered by the lack of a conditional gene ablation. We examined three mouse models of mammary‐specific ablation of Foxa1 in ductal epithelial cells to identify the best system for complete and mammary‐specific ablation of Foxa1. We found that MMTV‐Cre and MMTV‐rtTA;Tet‐On‐Cre led to partial deletion of Foxa1 and attenuated mammary duct formation, whereas Krt14‐Cre led to complete ablation of Foxa1 and abolished mammary duct formation, in Foxa1 loxP/loxP mice. These results demonstrate that Foxa1 is essential for mammary duct formation, and reveal a series of mouse models in which mammary expression of Foxa1 can be attenuated or completely blocked. Our study also suggests a potentially powerful model for complete ablation of Foxa1 in mammary epithelial cells using Krt14‐driven Cre expression in an inducible manner, such as Krt14‐rtTA;Tet‐On‐Cre . This model system will facilitate further in vivo functional studies of Foxa1 or other factors in mammary gland development and tumor formation and progression. genesis 54:277–285, 2016. © 2016 Wiley Periodicals, Inc.
Incorporating a Genetic Risk Score Into Coronary Heart Disease Risk Estimates
Jouni, Hayan, Austin, Erin , Brown, Sherry‐Ann , Kruisselbrink, Teresa , Isseh, Iyad , Haddad, Raad A., Marroush, Tariq S. , Broeckel, Ulrich , Schaid, Daniel J. , Montori, Víctor M. , Bailey, Kent R. , Austin, Erin E, Kruisselbrink, Teresa M, Isseh, Iyad N, Shameer, Khader, Kullo, Iftikhar J. , Shameer, Khader , Olson, Janet E. , Green, Robert C. , Montori, Victor M

Circulation | February 26, 2016 | Volume: 133 | Issue: 12 | Pages: 1181-1188

10.1161/circulationaha.115.020109 | PMID 26915630 Get It

Background— Whether knowledge of genetic risk for coronary heart disease (CHD) affects health-related outcomes is unknown. We investigated whether incorporating a genetic risk score (GRS) in CHD risk estimates lowers low-density lipoprotein cholesterol (LDL-C) levels. Methods and Results— Participants (n=203, 45–65 years of age, at intermediate risk for CHD, and not on statins) were randomly assigned to receive their 10-year probability of CHD based either on a conventional risk score (CRS) or CRS + GRS ( + GRS). Participants in the + GRS group were stratified as having high or average/low GRS. Risk was disclosed by a genetic counselor followed by shared decision making regarding statin therapy with a physician. We compared the primary end point of LDL-C levels at 6 months and assessed whether any differences were attributable to changes in dietary fat intake, physical activity levels, or statin use. Participants (mean age, 59.4±5 years; 48% men; mean 10-year CHD risk, 8.5±4.1%) were allocated to receive either CRS (n=100) or + GRS (n=103). At the end of the study period, the + GRS group had a lower LDL-C than the CRS group (96.5±32.7 versus 105.9±33.3 mg/dL; P =0.04). Participants with high GRS had lower LDL-C levels (92.3±32.9 mg/dL) than CRS participants ( P =0.02) but not participants with low GRS (100.9±32.2 mg/dL; P =0.18). Statins were initiated more often in the + GRS group than in the CRS group (39% versus 22%, P <0.01). No significant differences in dietary fat intake and physical activity levels were noted. Conclusions— Disclosure of CHD risk estimates that incorporated genetic risk information led to lower LDL-C levels than disclosure of CHD risk based on conventional risk factors alone. Clinical Trial Registration— URL: http://www.clinicaltrials.gov . Unique identifier: NCT01936675.
13C mannitol as a novel biomarker for measurement of intestinal permeability
Grover, Madhusudan , Camilleri, Michael , Hines, Jolaine, Burton, Duane D. , Ryks, Michael, Wadhwa, Abhishek , Sundt, Wendy, Dyer, Roy B. , Singh, Ravinder

Neurogastroenterology & Motility | February 26, 2016 | Volume: 28 | Issue: 7 | Pages: 1114-1119

10.1111/nmo.12802 | PMID 26914765 Get It

AbstractBackgroundGastrointestinal (GI) and non‐GI disorders are associated with altered intestinal permeability, which can be measured in vivo by urinary excretion after oral lactulose and mannitol ingestion. Inadvertent dietary consumption of 12Carbon (12C, regular) mannitol in food or from other sources may interfere with the test's interpretation. 13Carbon (13C) constitutes 1% of carbon in nature and 13C mannitol is a stable isotope. Our aim was to determine the performance of 13C mannitol for measurement of intestinal permeability.MethodsTen healthy volunteers underwent intestinal permeability assay using coadministered 12C mannitol, 13C mannitol and lactulose, followed by timed urine collections. Urinary sugar concentrations were measured using tandem high performance liquid chromatography–mass spectrometry.Key resultsWe found that 13C mannitol can be distinguishable from 12C mannitol on tandem mass spectrometry. In addition, 13C mannitol had ~20‐fold lower baseline contamination compared to 12C mannitol. We describe here the 13C mannitol assay method for the measurement of intestinal permeability.Conclusions & InferencesIn conclusion, 13C mannitol is superior to 12C mannitol for measurement of intestinal permeability. It avoids issues with baseline contamination and erratic excretions during the testing period.
Adding Laboratory Data to Hospital Claims Data to Improve Risk Adjustment of Inpatient/30-Day Postdischarge Outcomes
Pine, Michael , Naessens, James M. , Whitman, Kay, Reband, Agnes M. , Qian, Feng , Schindler, Joseph , Sonneborn, M, Roland, Jaclyn, Hyde, Linda A., Dennison, Barbara A. , Hannan, Edward L. , Fry, Donald E.

American Journal of Medical Quality | February 26, 2016 | Volume: 32 | Issue: 2 | Pages: 141-147

10.1177/1062860616629205 | PMID 26917809 Get It

Numerical laboratory data at admission have been proposed for enhancement of inpatient predictive modeling from administrative claims. In this study, predictive models for inpatient/30-day postdischarge mortality and for risk-adjusted prolonged length of stay, as a surrogate for severe inpatient complications of care, were designed with administrative data only and with administrative data plus numerical laboratory variables. A comparison of resulting inpatient models for acute myocardial infarction, congestive heart failure, coronary artery bypass grafting, and percutaneous cardiac interventions demonstrated improved discrimination and calibration with administrative data plus laboratory values compared to administrative data only for both mortality and prolonged length of stay. Improved goodness of fit was most apparent in acute myocardial infarction and percutaneous cardiac intervention. The emergence of electronic medical records should make the addition of laboratory variables to administrative data an efficient and practical method to clinically enhance predictive modeling of inpatient outcomes of care.
Racial differences in vestibular schwannoma
Carlson, Matthew L. , Glasgow, Amy E. , Habermann, Elizabeth B. , Sweeney, Alex D. , Link, Michael J. , Wanna, George B. , Glasgow, Amy E. , Marston, Alexander P, Marston, Alexander P. , Habermann, Elizabeth , Glasgow, Amy E

The Laryngoscope | February 26, 2016 | Volume: 126 | Issue: 9 | Pages: 2128-2133

10.1002/lary.25892 | PMID 26917495 Get It

Fatigue in patients with Behçet's syndrome: relationship with quality of life, depression, anxiety, disability and disease activity
İlhan, Birkan , Can, Meryem , Alıbaz-Öner, Fatma , Yılmaz-Öner, S. , Polat-Korkmaz, O., Özen, G., Kremers, Hilal Maradit , Maradit Kremers, Hilal, Özen, Gülşen , Mumcu, Gonca , Di̇reskeneli̇, Haner , Maradit Kremers, Hilal

International Journal of Rheumatic Diseases | February 26, 2016 | Volume: 21 | Issue: 12 | Pages: 2139-2145

10.1111/1756-185x.12839 | PMID 26913703 Get It

AbstractObjectivesFatigue is a common symptom of chronic inflammatory diseases. The objective of this study was to investigate fatigue in patients with Behçet's syndrome (BS) and to examine the relationship between fatigue and disease activity, quality of life, anxiety and depression.MethodsThis is a cross‐sectional study of 123 BS patients and 71 healthy controls in Turkey. All subjects completed the Multidimensional Assessment of Fatigue (MAF) questionnaire, Short form‐36 (SF‐36), Hospital Anxiety and Depression (HADS) scale and Health Assessment Questionnaire (HAQ). Disease activity among BS patients was assessed using the Behçet Syndrome Activity Scale (BSAS) and the physician's global assessment (PGA).ResultsBS patients had significantly higher MAF, HADS‐depression (HADS‐D) and HADS‐anxiety (HADS‐A) scores than the healthy controls (P < 0.001). Both the physical and mental components of the SF‐36 scale were impaired in BS patients (P = 0.0001). BS patients with active disease, depression and anxiety had significantly higher MAF scores compared to BS patients without active disease, depression and anxiety (P = 0.0001). MAF scores showed positive correlations with HADS‐A, HADS‐D, HAQ scores and negative correlations with SF‐36 mental and physical components. In regression analyses, depression, anxiety and physical dysfunction were significantly associated with fatigue, after adjusting for age, sex, SF‐36 physical and mental scores, HAQ, HADS‐A, HADS‐D and BSAS scores (P < 0.05). Decreases in SF‐36 physical and mental scores were significant predictive factors for high MAF score in healthy controls (P < 0.05).ConclusionsFatigue is common in clinically active BS patients compared with healthy controls and inactive BS patients. Depression, anxiety and physical dysfunction were significantly associated with fatigue.
4EBP1/c-MYC/PUMA and NF-κB/EGR1/BIM pathways underlie cytotoxicity of mTOR dual inhibitors in malignant lymphoid cells
Knorr, Katherine , Almada, Luciana L. , Schneider, Paula A., Peterson, Kevin L. , Flatten, Karen S., Dai, Haiming , Pratz, Keith W. , Hess, Allan D., Karp, Judith E. , Hendrickson, Andrea E. Wahner , Fernández-Zapico, Martín E. , Kaufmann, Scott H. , Yun, Seongseok , Vincelette, Nicole D. , Smith, B. Douglas , Dai, Haiming

Blood | February 25, 2016 | Volume: 127 | Issue: 22 | Pages: 2711-2722

10.1182/blood-2015-02-629485 | PMID 26917778 Get It

Key Points Agents that inhibit both complexes containing the mammalian target of rapamycin are particularly toxic to acute lymphocytic leukemia cells. This killing reflects engagement of a 4EBP1/c-MYC/PUMA axis downstream of mTORC1 and an NF-κB/EGR1/BIM axis downstream of mTORC2.
Impact of Glycoprotein IIb/IIIa Inhibitors Use on Outcomes After Lower Extremity Endovascular Interventions From Nationwide Inpatient Sample (2006–2011)
Arora, Shilpkumar , Panaich, Sidakpal , Patel, Nilay , Patel, Nileshkumar , Lahewala, Sopan , Thakkar, Badal, Savani, Chirag, Jhamnani, Sunny , Singh, Vikas , Patel, Nish , Patel, Samir , Sonani, Rajesh, Patel, Achint , Deshmukh, Abhishek , Chothani, Ankit , Bhatt, Parth , Mohamad, Tamam , Remetz, Michael S., Curtis, Jeptha P. , Attaran, Ramak R., Mena, Carlos, Schreiber, Theodore , Cleman, Michael , Forrest, John K. , Badheka, Apurva O., Tripathi, Byomesh , Patel, Jay N. , Grines, Cindy L. , Panaich, Sidakpal S

Catheterization and Cardiovascular Interventions | February 25, 2016 | Volume: 88 | Issue: 4 | Pages: 605-616

10.1002/ccd.26452 | PMID 26914274 Get It

ObjectiveThe aim of our study was to study the impact of glycoprotein IIb/IIIa inhibitors (GPI) on in‐hospital outcomes.BackgroundThere is paucity of data regarding the impact of GPI on the outcomes following peripheral endovascular interventions.MethodsThe study cohort was derived from Healthcare Cost and Utilization Project (HCUP) Nationwide Inpatient Sample (NIS) database between the years 2006 and 2011. Peripheral endovascular interventions and GPI utilization were identified using appropriate ICD‐9 Diagnostic and procedural codes. Two‐level hierarchical multivariate mixed models were created. The study outcomes were: primary (in‐hospital mortality and amputation studied separately) and secondary (composite of in‐hospital mortality and postprocedural complications). Hospitalization costs were also assessed.ResultsGPI utilization (OR, 95% CI, P‐value) was independently predictive of lower amputation rates (0.36, 0.27–0.49, <0.001). There was no significant difference in terms of in‐hospital mortality (0.59, 0.31–1.14, P 0.117), although GPI use predicted worse secondary outcomes (1.23, 1.03–1.47, 0.023). Following propensity matching, the amputation rate was lower (3.2% vs. 8%, P < 0.001), while hospitalization costs were higher in the cohort that received GPI ($21,091 ± 404 vs. 19,407 ± 133, P < 0.001).ConclusionsMultivariate analysis revealed GPI use in peripheral endovascular interventions to be suggestive of an increase in composite end‐point of in‐hospital mortality and postprocedural complications, no impact on in‐hospital mortality alone, significantly lower rate of amputation, and increase in hospitalization costs. © 2016 Wiley Periodicals, Inc.